Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment

被引:61
|
作者
Elkins, Ryan C. [1 ]
Davies, Mark R. [2 ]
Brough, Stephen J. [3 ]
Gavaghan, David J. [4 ]
Cui, Yi [5 ]
Abi-Gerges, Najah [1 ]
Mirams, Gary R. [4 ]
机构
[1] AstraZeneca, Global Safety Assessment, Global Safety Pharmacol, Macclesfield SK10 4TG, Cheshire, England
[2] AstraZeneca, R&D Informat, Clin Informat, Macclesfield SK10 4TG, Cheshire, England
[3] GlaxoSmithKline, Screening & Compound Profiling, Stevenage SG1 2NY, Herts, England
[4] Univ Oxford, Dept Comp Sci, Oxford OX1 3QD, England
[5] GlaxoSmithKline, Safety Assessment, Safety Pharmacol, Ware SG12 0DP, Herts, England
基金
英国国家替代、减少和改良动物研究中心; 英国工程与自然科学研究理事会;
关键词
High-throughput; Compound screening; Variability; Uncertainty; Cardiac safety; Action potential; Mathematical model; CELLULAR ELECTROPHYSIOLOGY MODELS; IONWORKS(TM) HT; ASSAY; HERG; OPTIMIZATION; PROLONGATION; VALIDATION; SIMULATION; RISK;
D O I
10.1016/j.vascn.2013.04.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of automated and high-throughput screening assays using cell lines. As a result of screening multiple ion-channels there is a need to integrate information, particularly for compounds affecting more than one current, and mathematical electrophysiology in-silico action potential models are beginning to be used for this. Methods: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks (R) Quattro (TM) screens when detecting block of I-Kr (hERG), I-Na (NaV1.5), I-CaL (CaV1.2), I-Ks (KCNQ1/minK) and I-to (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR (R) Tetra fluorescence screen for I-CaL (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. Results: There are significant levels of variability associated with high-throughput ion channel electrophysiology screens. This variability is of a similar magnitude for different cardiac ion currents and different compounds. Uncertainty in the Hill coefficients of reported concentration-effect curves is particularly high. Depending on a compound's ion channel blocking profile, the uncertainty introduced into whole-cell predictions can become significant. Discussion: Our technique allows confidence intervals to be placed on computational model predictions that are based on high-throughput ion channel screens. This allows us to suggest when repeated screens should be performed to reduce uncertainty in a compound's action to acceptable levels, to allow a meaningful interpretation of the data. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:112 / 122
页数:11
相关论文
共 50 条
  • [31] Apoptosis assessment in high-content and high-throughput screening assays
    Rens, Celine
    Shapira, Tirosh
    Pena-Diaz, Sandra
    Chao, Joseph D.
    Pfeifer, Tom
    Av-Gay, Yossef
    [J]. BIOTECHNIQUES, 2021, 70 (06) : 309 - 318
  • [32] Assessing Differential Variability of High-Throughput DNA Methylation Data
    Saddiki, Hachem
    Colicino, Elena
    Lesseur, Corina
    [J]. CURRENT ENVIRONMENTAL HEALTH REPORTS, 2022, 9 (04) : 625 - 630
  • [33] Assessing Differential Variability of High-Throughput DNA Methylation Data
    Hachem Saddiki
    Elena Colicino
    Corina Lesseur
    [J]. Current Environmental Health Reports, 2022, 9 : 625 - 630
  • [34] Deriving knowledge through data mining high-throughput screening data
    Diller, DJ
    Hobbs, DW
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (25) : 6373 - 6383
  • [35] Quality assessment and control of high-throughput sequencing data
    Watson, Mick
    [J]. FRONTIERS IN GENETICS, 2014, 5
  • [36] Lipid bilayer technologies for high throughput ion channel screening
    Schmidt, Jacob
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [37] High-throughput assessment of calcium sensitivity in skinned cardiac myocytes
    Lim, CC
    Helmes, MHB
    Sawyer, DB
    Jain, M
    Liao, RL
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 281 (02): : H969 - H974
  • [38] Automation of high-throughput crystal screening and data collection at SSRL
    Miller, MD
    Brinen, LS
    Cohen, A
    Deacon, AM
    Ellis, P
    McPhillips, SE
    McPhillips, TM
    Phizackerley, RP
    Soltis, SM
    van den Bedem, H
    Wolf, G
    Xu, QP
    Zhang, ZP
    [J]. SYNCHROTRON RADIATION INSTRUMENTATION, 2004, 705 : 1233 - 1236
  • [39] Practical methodologies for hit identification in high-throughput screening data
    Shun, Tongying
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (07) : 716 - 716
  • [40] High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment
    Di Veroli, Giovanni Y.
    Davies, Mark R.
    Zhang, Henggui
    Abi-Gerges, Najah
    Boyett, Mark R.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2013, 304 (01): : H104 - H117